BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 29783979)

  • 21. Lynch syndrome identification in a Brazilian cohort of endometrial cancer screened by a universal approach.
    Rosa RCA; Santis JO; Teixeira LA; Molfetta GA; Dos Santos JTT; Ribeiro VDS; Chahud F; Ribeiro-Silva A; Brunaldi MO; Silva WA; Ferraz VEF
    Gynecol Oncol; 2020 Oct; 159(1):229-238. PubMed ID: 32694065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MLH1 epimutation is a rare mechanism for Lynch syndrome: A case report and review of the literature.
    Zyla R; Graham T; Aronson M; Velsher L; Mrkonjic M; Turashvili G
    Genes Chromosomes Cancer; 2021 Sep; 60(9):635-639. PubMed ID: 33934415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome.
    Rahner N; Friedrichs N; Steinke V; Aretz S; Friedl W; Buettner R; Mangold E; Propping P; Walldorf C
    J Pathol; 2008 Jan; 214(1):10-6. PubMed ID: 17973250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EPM2AIP1 Immunohistochemistry Can Be Used as Surrogate Testing for MLH1 Promoter Methylation in Endometrial Cancer.
    Mrkonjic M; Turashvili G
    Am J Surg Pathol; 2022 Mar; 46(3):376-382. PubMed ID: 34772843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An Analysis of Clinical, Surgical, Pathological and Molecular Characteristics of Endometrial Cancer According to Mismatch Repair Status. A Multidisciplinary Approach.
    Dondi G; Coluccelli S; De Leo A; Ferrari S; Gruppioni E; Bovicelli A; Godino L; Coadă CA; Morganti AG; Giordano A; Santini D; Ceccarelli C; Turchetti D; De Iaco P; Perrone AM
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review.
    Metcalf AM; Spurdle AB
    Fam Cancer; 2014 Mar; 13(1):1-12. PubMed ID: 23880961
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Carnevali IW; Cini G; Libera L; Sahnane N; Facchi S; Viel A; Sessa F; Tibiletti MG
    Genes (Basel); 2023 Nov; 14(11):. PubMed ID: 38003003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Constitutional MLH1 methylation presenting with colonic polyposis syndrome and not Lynch syndrome.
    Kidambi TD; Blanco A; Van Ziffle J; Terdiman JP
    Fam Cancer; 2016 Apr; 15(2):275-80. PubMed ID: 26781822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrating Tumor Sequencing Into Clinical Practice for Patients With Mismatch Repair-Deficient Lynch Syndrome Spectrum Cancers.
    Dixon K; Asrat MJ; Bedard AC; Binnington K; Compton K; Cremin C; Heidary N; Lohn Z; Lovick N; McCullum M; Mindlin A; O'Loughlin M; Petersen T; Portigal-Todd C; Scott J; St-Martin G; Thompson J; Turnbull R; Mung SW; Hong Q; Bezeau M; Bosdet I; Tucker T; Young S; Yip S; Aubertin G; Blood KA; Nuk J; Sun S; Schrader KA
    Clin Transl Gastroenterol; 2021 Aug; 12(8):e00397. PubMed ID: 34397043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies.
    Ryan NAJ; Morris J; Green K; Lalloo F; Woodward ER; Hill J; Crosbie EJ; Evans DG
    JAMA Oncol; 2017 Dec; 3(12):1702-1706. PubMed ID: 28772289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modern day screening for Lynch syndrome in endometrial cancer: the KEM experience.
    Pauly N; Baert T; Schmutzler R; du Bois A; Schneider S; Rhiem K; Schömig-Markiefka B; Siemanowski J; Heikaus S; Traut A; Heitz F; Prader S; Ehmann S; Harter P; Ataseven B
    Arch Gynecol Obstet; 2021 Oct; 304(4):975-984. PubMed ID: 33710393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PMS2 involvement in patients suspected of Lynch syndrome.
    Niessen RC; Kleibeuker JH; Westers H; Jager PO; Rozeveld D; Bos KK; Boersma-van Ek W; Hollema H; Sijmons RH; Hofstra RM
    Genes Chromosomes Cancer; 2009 Apr; 48(4):322-9. PubMed ID: 19132747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis of microsatellite instability in endometroid carcinoma with deficient mismatch repair].
    Zhang YH; Wu HW; Wang J; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2021 May; 50(5):470-475. PubMed ID: 33915653
    [No Abstract]   [Full Text] [Related]  

  • 34. "Null pattern" of immunoreactivity in a Lynch syndrome-associated colon cancer due to germline MSH2 mutation and somatic MLH1 hypermethylation.
    Hagen CE; Lefferts J; Hornick JL; Srivastava A
    Am J Surg Pathol; 2011 Dec; 35(12):1902-5. PubMed ID: 22067334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequent loss of mutation-specific mismatch repair protein expression in nonneoplastic endometrium of Lynch syndrome patients.
    Wong S; Hui P; Buza N
    Mod Pathol; 2020 Jun; 33(6):1172-1181. PubMed ID: 31932681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome.
    Batte BA; Bruegl AS; Daniels MS; Ring KL; Dempsey KM; Djordjevic B; Luthra R; Fellman BM; Lu KH; Broaddus RR
    Gynecol Oncol; 2014 Aug; 134(2):319-25. PubMed ID: 24933100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mismatch repair deficiency testing in clinical practice.
    Buza N; Ziai J; Hui P
    Expert Rev Mol Diagn; 2016; 16(5):591-604. PubMed ID: 26895074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and molecular characteristics of DNA mismatch repair deficient endometrial cancer in a Japanese hospital-based population.
    Yamamoto A; Yamaguchi T; Suzuki O; Ito T; Chika N; Kamae N; Tamaru JI; Nagai T; Seki H; Arai T; Tachikawa T; Akagi K; Eguchi H; Okazaki Y; Ishida H
    Jpn J Clin Oncol; 2021 Jan; 51(1):60-69. PubMed ID: 32844218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MLH1 Promotor Hypermethylation in Colorectal and Endometrial Carcinomas from Patients with Lynch Syndrome.
    Helderman NC; Andini KD; van Leerdam ME; van Hest LP; Hoekman DR; Ahadova A; Bajwa-Ten Broeke SW; Bosse T; van der Logt EMJ; Imhann F; Kloor M; Langers AMJ; Smit VTHBM; Terlouw D; van Wezel T; Morreau H; Nielsen M
    J Mol Diagn; 2024 Feb; 26(2):106-114. PubMed ID: 38061582
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel case of endometrial dedifferentiated adenocarcinoma associated with MLH1 promotor hypermethylation and microsatellite instability.
    Liu X; Liu X; Wang X; Wu R; Zhang K; Liu B; Liu Q; Shao Y; Tang R; You J; Pei F
    Pathol Res Pract; 2018 Nov; 214(11):1904-1908. PubMed ID: 30173944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.